Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC Upcoming IO combinations for advanced HCC To our knowledge, IMbrave150 was the first phase 3 trial since 2007 to show a significant and clinically meaningful survival benefit with
Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer Dra. Renata D'Alpino, Oncologista Clínica do Grupo Oncoclínicas e Diretora Científica do Grupo Brasileiro de Tumores
IMbrave150: Updated overall survival (OS) data from a global Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the Atezolizumab and bevacizumab for upfront unresectable HCC IMbrave150 Trial: Combination Therapy in Advanced HCC
Patient-Reported Outcomes Improve with Combination Treatment for Patients With HCC IMbrave150: The first successful Phase III trial of a cancer IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab
Full Podcast: Experts provide an overview of current systemic treatment options for 1st line uHCC, Mehmet Akce, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of
Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150 Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150
Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021
Dr. Kim, Professor of Medicine, Moffit Cancer Center, describes the IMBRAVE 150 phase 3 study and whether the overall survival Patient-reported outcomes with atezolizumab plus bevacizumab Dr. Kaubisch on Treatment Options for HCC
Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Advanced HCC: IMbrave150 Trial
The IMpower150 study (NCT02366143) showed that atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel Introduction. The IMbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal
A review of the phase 3 IMbrave150 trial comparing atezolizumab-bevacizumab vs standard of care, sorafenib, as initial therapy HIMALAYA and IMbrave-150 for Hepatocellular Carcinoma: A Ask the author session with Prof. Michel Ducreux
Checkpoint inhibition in hepatocellular carcinoma Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma
A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable HCC Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara HCC podcast series part 1: The use of IO in unresectable HCC
Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III Peter R. Galle, MD, the director of the Medical Department at the University Medical Center Mainz and president-elect of the
IMbrave150 Trial: Frontline Treatment of Advanced HCC 2021 TASL HCC Single Topic Conference Satellite symposium - Roche Impact of IMbrave150 on theadvanced HCC treatment An overview of the IMbrave150 phase III trial data as they relate to the management of hepatocellular carcinoma.
Dr. Harding on the Goal of the IMbrave150 trial in HCC This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, and consultant medical oncologist in the
TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and
We met up with Dr Michel Ducreux at ESMO 2018 who provided a brief review of the current treatment landscape for Updates from IMbrave 150 in HCC
Andreas Kaubisch, MD, associate attending physician, Montefiore Medical Center, Albert Einstein College of Medicine, discusses Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable
Real-world experience of Impower150 regimen for EGFR+ NSCLC Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study
With Prof. Jean-François Dufour about this journal paper: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard
An expert clinical review of data from the EGFR-mutated subset included in the IMpower-150 trial looking at the addition of IMbrave150 showed consistent clinically meaningful treatment benefit and safety with 12 mo of additional follow-up. James J. Harding, MD, regional director of Early Drug Development at Memorial Sloan Kettering Cancer Center, discusses the
AACR 2021: Dra. Renata D'Alpino aborda a análise do estudo IMbrave150 Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of immune
IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC IMbrave150 in Unresectable HCC
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma The role of sorafenib in the first-line treatment of HCC as seen in the IMbrave150 trial. For more resources and information IMbrave150 analysis. Oncologist. 2025 Sep 1;30(9):oyaf269. doi: 10.1093 IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with
IMBrave150 Regimen: Managing Varices Jawaban Webinar 5 Years of IMbrave150 - Milestones and Future Opportunities in HCC #Dokter #nilai100
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Richard S. Finn, MD, discusses the significance of the results presented on the recent IMbrave150 study in unresectable
Impact of IMbrave150 Trial: APAC Expert Review Now Published IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared IMbrave150: updated data on atezo plus bev versus sorafenib in HCC
IMbrave150 Phase III Design, Results, and Practical Implications Study Details | NCT03434379 | A Study of Atezolizumab in • Here, we report updated efficacy data for IMbrave150 with 12 mo of additional follow-up (median follow-up: 15.6 mo). Page 3. Study design. Key eligibility.
Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021 Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC
Impact of IMbrave150 on theadvanced HCC treatment landscape: How dose it improve patient outcomes? Prof Richard Finn speaks to ecancer in an online interview for the virtual AACR 2021 meeting about the updated safety and An influx of treatments are emerging against hepatocellular carcinoma (HCC), a common malignancy with huge unmet needs,
Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase III HIMALAYA trial which investigated The use of Immunotherapy (IO) in unresectable Hepatocellular Carcinoma (HCC)
Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), The IMbrave150 trial showed significantly better overall survival and progression-free survival outcomes with atezolizumab plus bevacizumab than
An overview of the phase III IMbrave150 trial, inclusion criteria, primary/secondary end points, and practical implications. Website: Daniel Catenacci, MD, University of Chicago, Chicago, IL, provides an overview of some of the exciting data presented at this
7/1/2021. Ghassan K. Abou-Alfa, MD, MBA, leads a discussion on the management of varices occurring in patients with metastatic
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based Dr. Li on the Subgroup Analysis of the IMbrave150 Trial in Older Patients With HCC ASCO GI 2021: trial updates
IMbrave150: updated overall survival data from a global Depth and Duration of Response Are Associated with Survival in In this animated video article, we present the phase III HIMALAYA study, which investigated tremelimumab and durvalumab for
Key updates from ASCO GI 2021 First-line treatment options for advanced HCC including sorafenib, lenvatinib, and atezolizumab-bevacizumab as systemic Additionally, an exploratory analysis of the patients with Vp4 HCC (15%) enrolled on the IMbrave-150 trial also demonstrated improved efficacy
Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab Dr.Molham Khalil.
Treatment of advanced HCC IMbrave - 150 trail || علاج HCC IMbrave المتقدم IMpower-150: EGFR-Mutated Subset Analysis Updated efficacy and safety data from IMbrave150: Atezolizumab
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC? Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy
New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC Michel Ducreux, ESMO 2018 – Exploring new treatment options for hepatocellular carcinoma
IMbrave150 Phase III Trial for MHCC Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides
Dr. Li, Assistant Clinical Professor, City of Hope, shares his impressions of the IMBRAVE 150 study particularly relating to patient